A Prospective, Observational Cohort Study on the Clinical Impact of Novel Monoclonal Antibodies in B-cell Non-Hodgkin Lymphoma in Italian Clinical Practice (FIL_MAB)
A Prospective, Observational Cohort Study to Evaluate the Clinical Impact of Novel Monoclonal Antibodies (MAB) in B-cell Non-Hodgkin Lymphoma (NHL) in Italian Clinical Practice
Sponsor: Fondazione Italiana Linfomi - ETS
This observational or N/A phase trial investigates Non-Hodgkin Lymphoma, B-cell and is currently actively recruiting participants. Fondazione Italiana Linfomi - ETS leads this study, which shows 7 recorded versions since 2023 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
7 versions recorded-
Jan 2026 — Present [monthly]
Recruiting
-
Oct 2025 — Jan 2026 [monthly]
Recruiting
-
Sep 2025 — Oct 2025 [monthly]
Recruiting
-
Feb 2025 — Sep 2025 [monthly]
Recruiting
-
Sep 2024 — Feb 2025 [monthly]
Recruiting
▶ Show 2 earlier versions
-
Jul 2024 — Sep 2024 [monthly]
Recruiting
Status: Not Yet Recruiting → Recruiting
-
Sep 2023 — Jul 2024 [monthly]
Not Yet Recruiting
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Fondazione Italiana Linfomi - ETS
- Roche Pharma AG
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Alessandria, Italy , Ancona, Italy , Avellino, Italy , Aviano, Italy , Bari, Italy , Barletta, Italy , Bergamo, Italy , Biella, Italy , Bologna, Italy , Brescia, Italy and 44 more locations